OrthoPediatrics Q2 2024 Earnings Report
Key Takeaways
OrthoPediatrics Corp. announced its Q2 2024 financial results, achieving record revenue of $52.8 million, a 33% increase compared to the same period last year. The company helped a record 32,000 children, marking a 52% increase from Q2 2023. They reaffirmed their full-year 2024 revenue guidance of $200.0 million to $203.0 million.
Helped a record 32,000 children in Q2 2024, a 52% increase year-over-year.
Generated record total revenue of $52.8 million in Q2 2024, up 33% year-over-year.
Worldwide Trauma & Deformity revenue grew 37%, Scoliosis revenue grew 26%, and Sports Medicine/Other revenue increased 17% year-over-year.
Received Breakthrough Device Designation from FDA for eLLiTM Growing Rod System.
OrthoPediatrics
OrthoPediatrics
OrthoPediatrics Revenue by Segment
OrthoPediatrics Revenue by Geographic Location
Forward Guidance
The Company reiterated its revenue guidance of $200.0 million to $203.0 million, representing growth of 34% to 36% over 2023 revenue. The Company reiterated annual set deployment to be less than $20.0 million and reiterated $8.0 million to $9.0 million of Adjusted EBITDA for the full year of 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income